XFOR CIK: 1501697

X4 Pharmaceuticals, Inc

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
87.9
FY22:
129
FY23:
122
FY24:
112
FY25:
262
(positive)
Change from FY21 to FY25
millions USD
FY21:
29.3
FY22:
26.9
FY23:
25.2
FY24:
34.3
FY25:
28.9
Total assets
Change from FY21 to FY25
millions USD
FY21:
117
FY22:
156
FY23:
147
FY24:
146
FY25:
290

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
14.0
FY22:
22.3
FY23:
22.9
FY24:
32.9
FY25:
25.8
(negative)
Change from FY21 to FY25
millions USD
FY21:
38.7
FY22:
59.2
FY23:
73.3
FY24:
91.4
FY25:
78.4
(positive)
Change from FY21 to FY25
millions USD
FY21:
64.4
FY22:
74.1
FY23:
51.1
FY24:
22.1
FY25:
186
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
117
FY22:
156
FY23:
147
FY24:
146
FY25:
290

All amounts in millions USD Data source:SEC EDGAR